More on FGEN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.71 |
|
|||
| Open | $9.71 | ||||
| 52 Wk High | $31.90 | ||||
| 52 Wk Low | $14.38 | ||||
| Day High | $9.71 | ||||
| Day Low | $9.71 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 116,000 | ||||
- Kyntra Bio reports positive results from prostate cancer drug trial
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be P
- Form SCHEDULE 13G/A KYNTRA BIO, INC. Filed by: ARMISTICE CAPITAL, LLC
- Form 4 KYNTRA BIO, INC. For: Feb 03 Filed by: Wettig Thane
- Form 4 KYNTRA BIO, INC. For: Feb 03 Filed by: DeLucia David
- Form 8-K FIBROGEN INC For: Jan 07
- FibroGen rebrands as Kyntra Bio, trades under KYNB starting January 8
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
- FibroGen's roxadustat gets orphan drug status for rare blood disorder
- Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
Entities mentioned with FGEN
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- AdCom | View Related Stories »
- Goldman Sachs | View Related Stories »
- Morgan Stanley | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
